Recently Added |View More
Document
Is Subcutaneous Immunotherapy Ready for Prime Time? Join the June 23 webinar
Physicians are invited to join a panel of experts from Roswell Park Comprehensive Cancer Center on Tuesday, June 23 for a discussion on the use of subcutaneous immunotherapy.
News
Roswell Park Announces Positive Progress in Clinical Trial of Novel Immunotherapy SurVaxM
Roswell Park Comprehensive Cancer Center announced that the ongoing phase 2B SURVIVE clinical trial of SurVaxM in glioblastoma will continue following an interim analysis of trial data.
News
A meta-analysis led by a researcher at Roswell Park Comprehensive Cancer Center has identified key factors that could improve outcomes for cancer patients treated with immune checkpoint inhibitors (ICIs) before or after a solid-organ transplant.
News
Experts from Roswell Park Comprehensive Cancer Center will give remarks on racial and ethnic disparities in outcomes among people with metastatic breast cancer; risk patterns for second cancers associated with human papillomavirus (HPV); ...
News
Roswell Park presentations include findings from KOMET-001 in AML, new insights on risk of organ rejection after ICI.
News
Working at Roswell Park will afford you incredible opportunities to work alongside some of the nation’s foremost clinicians and researchers to broaden your career experiences and be part of a team that eases the burden of cancer.
News
Prantesh Jain, MD, FACP, Assistant Professor of Oncology, Department of Medicine at Roswell Park Comprehensive Cancer Center, will share initial results of the study during the 2025 annual meeting of the American Association for Cancer ...
News
Roswell Park Researchers to Discuss Recent Discoveries and Critical Issues in Oncology at AACR 2025
Researchers from Roswell Park Comprehensive Cancer Center will report their latest findings to colleagues from around the world at the 2025 annual meeting of the American Association for Cancer Research (AACR) in Chicago, Illinois, April 25-30.
News
Clinical Trial Utilizes Novel CAR Target for Relapsed/Refractory Multiple Myeloma
Most multiple myeloma patients with relapsed/refractory disease will undergo CAR T-cell therapy targeting B-cell maturation antigen (BCMA), a protein found on multiple myeloma cells.
This site is intended for healthcare professionals
Click your preferred app store below to download our free mobile app — exclusively for physicians and physician offices — for direct access to a complete, up-to-date directory of Roswell Park physicians wherever you go. Email or call to refer a patient or ask a question with a click of a button.
BROADCASTMED